legalon sil infusioonilahuse pulber
madaus gmbh - silümariin - infusioonilahuse pulber - 350mg 4tk
allergodil ninasprei, lahus
viatris healthcare limited - aselastiin - ninasprei, lahus - 1,5mg 1ml 20ml 1tk; 1,5mg 1ml 22ml 1tk; 1,5mg 1ml 10ml 1tk; 1,5mg 1ml 17ml 1tk
arthryl õhukese polümeerikattega tablett
meda pharma sia - glükoosamiin - õhukese polümeerikattega tablett - 589mg 60tk
allergodil 0,1% ninasprei, lahus
viatris healthcare limited - aselastiin - ninasprei, lahus - 1mg 1ml 10ml 1tk
treclinac geel
viatris healthcare limited - klindamütsiin+tretinoiin - geel - 10mg+0,25mg 1g 60g 1tk
cyklokapron õhukese polümeerikattega tablett
meda ab - traneksaamhape - õhukese polümeerikattega tablett - 500mg 50tk; 500mg 100tk
cyklokapron õhukese polümeerikattega tablett
ideal trade links uab - traneksaamhape - õhukese polümeerikattega tablett - 500mg 30tk
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.